Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 1:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 373 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Central Line Clear all
Completed No phase listed Observational

Correlation of Venous Oxygen Saturation Measurements by Non-invasive Mespere Venous Oximeter and Central Venous Catheter

NCT01908790
View directory record Official record
Conditions
Validation of Oximeter System
Interventions
Mespere Venous Oximeter, Avoximeter 4000
Device
Lead sponsor
Mespere Lifesciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 28, 2015 · Synced Oct 30, 2026, 1:36 PM EDT
Withdrawn Phase 2 Interventional

Study of Capecitabine and Cetuximab as First-Line Therapy in Patients With Metastatic Wild Type Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Colorectal Cancer

NCT00954876
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
capecitabine and cetuximab
Drug
Lead sponsor
Translational Genomics Research Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Oct 20, 2022 · Synced Oct 30, 2026, 1:36 PM EDT
Terminated Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma

NCT03656536
View directory record Official record
Conditions
Unresectable Cholangiocarcinoma, Metastatic Cholangiocarcinoma
Interventions
Pemigatinib, Gemcitabine, Cisplatin
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
36
States / cities
Phoenix, Arizona • Greenbrae, California • Orange, California + 29 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 30, 2026, 1:36 PM EDT
Recruiting Phase 4 Interventional

Study Evaluating Safety, Tolerability, and Metabolism of Niraparib

NCT06412120
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Niraparib
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older · Female only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
3
States / cities
Fort Lauderdale, Florida • Jacksonville, Florida • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 30, 2026, 1:36 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer

NCT03742102
View directory record Official record
Conditions
Triple Negative Breast Neoplasms
Interventions
Durvalumab, Capivasertib, Oleclumab, Paclitaxel, Trastuzumab deruxtecan, Datopotamab deruxtecan
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years · Female only
Enrollment
243 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
8
States / cities
Tucson, Arizona • Columbia, Maryland • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 30, 2026, 1:36 PM EDT
Recruiting Phase 3 Interventional

Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma

NCT07555938
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Cevostamab, Pomalidomide, Dexamethasone, Daratumumab, Elotuzumab, Carfilzomib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
10
States / cities
Duarte, California • Irvine, California • New Haven, Connecticut + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 30, 2026, 1:36 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety Study of Two Repeat Doses of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults

NCT01124565
View directory record Official record
Conditions
Lateral Canthal Lines, Crow's Feet, Facial Wrinkles
Interventions
RT001
Drug
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
3
States / cities
Birmingham, Alabama • San Diego, California • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jan 17, 2014 · Synced Oct 30, 2026, 1:36 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).

NCT03164616
View directory record Official record
Conditions
Non Small Cell Lung Cancer NSCLC
Interventions
Durvalumab, Tremelimumab, Abraxane + carboplatin, Gemcitabine + cisplatin, Gemcitabine + carboplatin, Pemetrexed + carboplatin, Pemetrexed + cisplatin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
1,186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
16
States / cities
Phoenix, Arizona • Bakersfield, California • Santa Monica, California + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 30, 2026, 1:36 PM EDT
Completed No phase listed Observational

Central Venous Access Catheter Placement Using the Sonic Flashlight

NCT00330590
View directory record Official record
Conditions
Catheterization, Central Venous
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
150 participants
Timeline
Ends 2006
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 15, 2008 · Synced Oct 30, 2026, 1:36 PM EDT
Completed Phase 3 Interventional Results available

Chlorhexidine Gluconate Cleansing in Preventing Central Line Associated Bloodstream Infection and Acquisition of Multi-drug Resistant Organisms in Younger Patients With Cancer or Undergoing Donor Stem Cell Transplant

NCT01817075
View directory record Official record
Conditions
Bacterial Infection, Benign Neoplasm, Malignant Neoplasm, Methicillin-Resistant Staphylococcus Aureus Infection, Myeloid Neoplasm, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia
Interventions
Chlorhexidine Gluconate Skin Cleanser, Laboratory Biomarker Analysis, Mild Soap Skin Cleanser, Questionnaire Administration
Procedure · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
2 Months to 21 Years
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
53
States / cities
Duarte, California • Long Beach, California • Los Angeles, California + 44 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2021 · Synced Oct 30, 2026, 1:36 PM EDT
Active, not recruiting Phase 3 Interventional

DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)

NCT05566795
View directory record Official record
Conditions
Low-grade Glioma, Rapidly Accelerated Fibrosarcoma (RAF) Altered Glioma, Pediatric Low-grade Glioma
Interventions
Tovorafenib, Chemotherapeutic Agent
Drug
Lead sponsor
Day One Biopharmaceuticals, Inc.
Industry
Eligibility
Up to 25 Years
Enrollment
418 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
38
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 33 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 30, 2026, 1:36 PM EDT
Completed No phase listed Observational

Study on Prevalence and Impact of Brain Metastases on Survival in Lung Cancer by Line of Treatment

NCT06557967
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Lung Cancer, Metastatic Cancer, Brain and Central Nervous System Cancer
Interventions
No drug
Other
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
22,517 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 9, 2024 · Synced Oct 30, 2026, 1:36 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma

NCT04194775
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Nofazinlimab (CS1003)+Lenvatinib, Nofazinlimab (CS1003) Placebo+Lenvatinib
Drug
Lead sponsor
CStone Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
534 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
5
States / cities
Coronado, California • Rialto, California • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 30, 2026, 1:36 PM EDT
Completed Phase 3 Interventional Results available

Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy

NCT00790036
View directory record Official record
Conditions
Diffuse Large B-cell Lymphoma
Interventions
Everolimus, Everolimus Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
742 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
34
States / cities
Chandler, Arizona • Fayetteville, Arkansas • La Jolla, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2017 · Synced Oct 30, 2026, 1:36 PM EDT
Recruiting Phase 2 Interventional

Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus

NCT02479698
View directory record Official record
Conditions
Acquired Immunodeficiency Syndrome, BK Virus Infection, Human Immunodeficiency Virus, JC Virus Infection, Malignant Neoplasm, Merkel Cell Carcinoma, Merkel Cell Polyomavirus Infection, Viral Encephalitis
Interventions
Allogeneic BK-specific Cytotoxic T-lymphocytes, Laboratory Biomarker Analysis
Biological · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 30, 2026, 1:36 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines

NCT00888914
View directory record Official record
Conditions
Lateral Canthal Lines, Crow's Feet, Facial Wrinkles
Interventions
RT001, Vehicle Comparator
Drug · Other
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
30 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
4
States / cities
San Francisco, California • New York, New York • White Plains, New York
Source: ClinicalTrials.gov public record
Updated Nov 19, 2013 · Synced Oct 30, 2026, 1:36 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Efficacy of Ben-Guard Garment in Reducing Pediatric Central Line Complications

NCT05109338
View directory record Official record
Conditions
Central Venous Catheters
Interventions
Ben-Guard Garment
Device
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
0 Years to 10 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 31, 2024 · Synced Oct 30, 2026, 1:36 PM EDT
Completed Phase 4 Interventional

Letrozole in Treating Postmenopausal Women With Metastatic Breast Cancer

NCT00014638
View directory record Official record
Conditions
Breast Cancer
Interventions
letrozole
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
20
States / cities
Berkeley, California • Long Beach, California • Hollywood, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2013 · Synced Oct 30, 2026, 1:36 PM EDT
Completed No phase listed Observational

Post-Marketing Study to Assess Complication Rates of Oncology Patients With Ports and Peripheral IVs

NCT02792764
View directory record Official record
Conditions
PORTs/Peripheral IVs Complication Rates
Interventions
Not listed
Lead sponsor
C. R. Bard
Industry
Eligibility
21 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
2
States / cities
Quincy, Illinois • Shreveport, Louisiana
Source: ClinicalTrials.gov public record
Updated Jun 8, 2016 · Synced Oct 30, 2026, 1:36 PM EDT
Terminated Phase 2 Interventional

GM-CT-01 Plus 5-Fluorouracil as Third- or Fourth-Line Therapy for Metastatic Colorectal Cancer

NCT00110721
View directory record Official record
Conditions
Colorectal Cancer
Interventions
GM-CT-01 plus 5-Fluorouracil
Drug
Lead sponsor
Galectin Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
4
States / cities
Waterbury, Connecticut • Port Saint Lucie, Florida • New Orleans, Louisiana + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2012 · Synced Oct 30, 2026, 1:36 PM EDT
Completed Phase 3 Interventional Results available

Phase III Open Label Study of MEDI 4736 With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck Cancer

NCT02551159
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Head and Neck
Interventions
MEDI4736, Tremelimumab, MEDI4736+Tremelimumab, Cetuximab, 5-fluorouracil (5FU), Cisplatin, Carboplatin
Biological · Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
823 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
19
States / cities
Aurora, Colorado • Washington D.C., District of Columbia • Fort Myers, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2021 · Synced Oct 30, 2026, 1:36 PM EDT
Terminated Phase 2 Interventional Results available

Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer

NCT02093962
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
TH-302 combination with pemetrexed, Matched placebo in combination with pemetrexed
Drug
Lead sponsor
ImmunoGenesis
Industry
Eligibility
18 Years and older
Enrollment
265 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
29
States / cities
Birmingham, Alabama • Chandler, Arizona • Encinitas, California + 25 more
Source: ClinicalTrials.gov public record
Updated May 16, 2025 · Synced Oct 30, 2026, 1:36 PM EDT
Completed No phase listed Observational

Risk Factors for Thrombosis in Children With Central Venous Lines

NCT04117217
View directory record Official record
Conditions
Pediatric Venous Thromboembolism
Interventions
Labs drawn
Diagnostic Test
Lead sponsor
University of Arizona
Other
Eligibility
6 Months to 17 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 22, 2024 · Synced Oct 30, 2026, 1:36 PM EDT
Not listed Phase 3 Interventional

A Multi-Centered, Two-Arm, Randomized Study Comparing the Effects of AAT-023 (Zuragen) Solution, and Heparin on the Incidence of Catheter Related Blood Stream Infections in Tunneled Chronic Central Venous Catheters for Dialysis

NCT00628680
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
AAT-023 solution (Zuragen), Heparin
Device · Drug
Lead sponsor
Ash Access Technology
Industry
Eligibility
18 Years and older
Enrollment
415 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
22
States / cities
Bakersfield, California • Lynwood, California • Middlebury, Connecticut + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2008 · Synced Oct 30, 2026, 1:36 PM EDT